DBV Technologies (NASDAQ:DBVT) Posts Earnings Results, Misses Expectations By $0.48 EPS

DBV Technologies (NASDAQ:DBVT) posted its quarterly earnings data on Thursday. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48), FiscalAI reports. DBV Technologies had a negative return on equity of 122.92% and a negative net margin of 3,506.53%.The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.03 million.

Here are the key takeaways from DBV Technologies’ conference call:

• DBV said it remains on track to submit an optimized BLA for Viaskin Peanut in the third quarter of 2026, and emphasized that the FDA has not requested additional data. Management said the remaining work is focused on formatting, mapping, and organizing existing CMC and biostatistics information.
• The company said it is building out commercial infrastructure in anticipation of a possible approval, including market access, patient services, brand readiness, field force planning, and launch operations. Management also said it is preparing manufacturing and supply-chain capacity for potential peak demand.
• DBV announced that recruitment has closed for the COMFORT Toddlers safety study in children ages one to three, and it still expects to file by year-end. The study is a six-month supplemental safety trial with no efficacy component.
• New clinical and epidemiological data were presented supporting Viaskin Peanut, including additional VITESSE subgroup analyses showing consistent treatment effects and a new prevalence study indicating U.S. pediatric peanut allergy remains around 2%. Management said this reinforces the size and persistence of the addressable market.
• The company said it is funded into the third quarter of 2027, giving it runway to support operations and commercial preparedness. Management described THRIVE as an early-stage, first-of-its-kind phase II study in infants, but said it is not currently intended as a registration trial.

DBV Technologies Price Performance

Shares of DBVT opened at $14.70 on Friday. The firm has a fifty day moving average price of $17.14 and a 200 day moving average price of $19.48. The stock has a market cap of $870.39 million, a PE ratio of -4.19 and a beta of -0.95. DBV Technologies has a 1-year low of $8.51 and a 1-year high of $26.18.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citizens Jmp raised their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Finally, Guggenheim restated a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada purchased a new position in DBV Technologies in the fourth quarter worth $34,000. Truvestments Capital LLC increased its position in DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in DBV Technologies in the 4th quarter valued at about $115,000. Cetera Investment Advisers acquired a new stake in DBV Technologies during the fourth quarter worth approximately $251,000. Finally, Two Sigma Investments LP purchased a new stake in shares of DBV Technologies in the third quarter valued at $167,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.